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Clinical and Molecular Findings
Ben C.J. Hamel, Arie P.T. Sm its, Barto J. O tten, B ellinda van  den Helm, Hans-Hilger Ropers, 
and Edwin C.M. M arim an
Department of Human Genetics (B .C.J. FL, A . P. T. S  . , B.vxl.H ., H . - H . R E . C M M J  and Department of Paediatrics 
(B.J.OJ, University Hospital, Nijmegen, The Netherlands
We report on severa l m em bers of a fam ily  
with varying degrees o f  X -linked m ental 
retardation (XLMR), iso la ted  grow th h o r­
mone deficiency (IGHD), and in fantile  b e ­
haviour but w ithout other con sisten t p h en o­
typic abnormalities. Male patients continued  
to grow until w ell in to  th e ir  tw en ties and  
reached a height rangin g  from  135 to 159 cm. 
Except one, all fem ale carriers w ere m en­
tally normal; their adu lt h e ig h t ranged from  
159 to 168 cm. By lin k age stud ies w e have a s­
signed the underlying gen etic  defect to the  
Xq24-q27.3 region, w ith  a m axim um  lod  
score of Z = 3.26 at 0 = 0.0 for the DXS294 lo ­
cus. The XLMR-IGHD phenotype in  th ese  
patients may be due to p leiotrop ic effects of 
a single gene or it  m ay rep resen t a con tigu ­
ous gene syndrome. © 199<> Wiley-Uss, Inc.
KEY WORDS: X -linked m enta l retardation ,
iso la ted  grow th horm one de­
ficiency, gene loca liza tion
INTRODUCTION
X-linked mental retardation (XLMR) is an important 
cause of mental handicap. Opitz 119861 calculated the 
prevalence of all XLMR a t 1/296 for both sexes. Neri 
et al. 11994] listed 127 conditions with XLMR, includ­
ing various nonspecific forms. In contrast, X-linked iso­
lated growth hormone deficiency (IGHD) is very rare 
[Phillips and Cogan, 1994; Perez Jurado and Argente, 
1994]. IGHD has been reported in combination with 
agammaglobulinemia a t Xq21.3-q22, the site of the 
X-linked agammaglobulinemia (XLA) gene [Duriez
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et al., 1994], Growth hormone deficiency has also been 
described in a boy with a dup(XKql3.3-q2L2) 
[Yokoyama et al., 1992], and Ogata et al. [1992] have 
hypothesized on the localization of growth gene(s) in 
the pseudoautosomal region. Moreover, growth hor­
mone deficiency is one manifestation in patients with 
X-linked recessive panhypopituitarism, a rare but well- 
defined genetic condition [Phelan et al,, 1971; Schimkc 
et al., 1971; Zipfet al., 1977].
While there are forms of XLMR that are associated 
with short stature [Neri et al., 19941, the combination 
of XLMR with IGHD has not been described yet. Here 
we report on a family in which mental retardation and 
IGHD eo-segregate as an X-linked trait. Linkage stud­
ies have assigned the underlying gene(s) to the distal 
half of Xq thereby indicating that we are dealing with a 
“novel” disorder.
MATERIALS AND METHODS
C linical Report and Fam ily History
A four generation family included eight male pa­
tients with variable mental retardation and short 
stature (Fig 1). The propositus (HI-9) was examined in 
1976 by an endocrinologist at the age of 28 years when 
the diagnosis of IGHD was made. lie  was born at term, 
after an uneventful pregnancy and delivery. Motor de­
velopment was normal. He attended a special school for 
children with learning difficulties and thereafter 
worked in a sheltered environment. At the age of about 
13 years he weighed 32 kg at a height of 127 cm. There 
were no health complaints. He shaved once or twice a 
week, and had regular erections and ejaculations. Re­
markably he had continued to grow into his twenties. 
Age at pubarche is unknown. On examination height 
was 155 cm. Besides mild gynaeeomastia, no other ab­
normality was seen; in particular he had normal exter­
nal genitalia, with a testicular volume of 20 ml. Labo­
ratory investigations gave normal results for cortisol, 
thyroxine, T3, testosterone, LH, and FSH. G1.1 concen-
3fore and after insulin i
caemia were all below 1 mU/L. Radiographs of the skull 
showed a small sella turcica. He had an adult bone ago.
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Fig. 1 . Pedigree of the family with X-linked mental retardation and isolated growth hormone defi­
ciency. Haplotypes are shown, which have been constructed from informative marker« in the region 
Xq24-q28. The co~segregating haplotype has been marked by a cross-hatched bar.
When seen again at the age of 45 years (Fig. 2), he 
showed an infantile behaviour. Results of physical and 
laboratory examination are given in Tables I and II.
II-6 died for unknown reasons at the age of 18 years. 
He was mildly mentally retarded and attained a height 
of 143 cm.
II-7 died at the age of 72 years because of leukemia. 
Reportedly he was mentally dull and had a height of 
158 cm.
II-8 died at the age of 51 years because of food aspi­
ration. He had been institutionalized because of mental 
retardation. His height was 135 cm. At autopsy the 
sella turcica and the pituitary gland appeared very 
small; the latter weighed 170 mg, while the normal 
mean adult weight is about 600 mg [Kovics and 
Horvath, .1986].
Patients III-3, III-6, III-7, and IV-6 were all born at 
term after an uneventful pregnancy and delivery.
III-3 was severely growth retarded and attended a 
special school for children with learning difficulties. At 
the age of 20 years he had a height age of 10 years and 
a bone age of 12 years. He continued to grow into his 
twenties. Psychometric testing (WAIS) at the age of 47 
years demonstrated a total IQ of 81 (verbal: 89, perfor­
mance; 74). When seen at the age of 50 years (Fig. 3), 
he used antiepileptic therapy, though he had not had 
convulsions for a long time. Otherwise he was healthy. 
His behaviour was infantile. He lived and worked in a 
sheltered environment. Results of physical and labora­
tory examination are given in Tables I and II.
III-6 was also short statured and attended a special 
school for chidden with learning difficulties. At the age 
of 16 years he had a height age of 8 1/2 years and a bone 
age of 10 years. He reached his final height in his twen­
ties. When seen at the age of 45 years (Fig. 4), he lived 
and worked in a sheltered environment and did not 
have any health problems. He showed an infantile be­
haviour. Results of physical and laboratory examina­
tions are given in Tables I and II.
III-7 had, as the first in his family, postaxial poly- 
dactyly of both hands. Postnatally he was operated 
for a possible duodenal stenosis. He also was short 
statured. He was institutionalized for his mental retar­
dation. At the age of 11 years he had a height age of 7 
years and a bone age of 5 years. At age 16, he weighed 
33 kg at a height of only 130 cm, but he, too, continued 
to grow into his twenties. He was seen at the age of 39 
years (Fig. 5). There were no particular health prob-
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Fig. 2. Patient III-9 at the age o f  45 years.
lems. Results of physical and laboratory examinations 
are given in Tables I and II.
IV-6 had a b irth  weight of 4,500 g. Motor milestones 
were reached within normal limits. Gradually he be­
came short statured with truncal obesity and a puffy 
face, as seen in hypothalamic disorders. At the age of 4 
years, he weighed 20 kg and his height was 100 cm. He
attended a special school for children with learning dif­
ficulties. In course of time many investigations were 
performed with normal results for thyroid function, 
cortisol, LH/FSH/TSH/prolactine after LH-RH, and 
TRH stimulation. L-DOPA and arginine GH stimula­
tion tests gave maximal GH levels of 6 mU/L, thereby 
providing clear evidence for a total GH deficiency. Cere­
bral CT-scan was normal and radiographs of the skull 
showed a small sella turcica. At the age of 9 years and 
8 months his bone age was 7.9 years. At the age of 10 
years GH replacement therapy was started. Because of 
secondary hypothyroidism during GH therapy, thyrox­
ine was supplemented at the age of about 14 years, At 
the age of 15 years he had not yet entered puberty. He 
showed an infantile behaviour. Results of physical and 
laboratory examinations just before the start of GH 
treatm ent are given in Tables I and IL
Figure 6 shows height growth curves of patients II-7, 
II-8, HI-9 and IV-6.
Obligate carriers (1-2, II-2, II-4, and III-10) and car­
riers identified by linkage analysis with flanking mark­
ers (III-2 and III-5) had heights ranging from 159 to 
168 cm, i.e., a t or above the 10th centile; they were all 
mentally normal with the exception of III-2 who at­
tended a special school for children with learning diffi­
culties and remained unmarried.
Linkage Studies
Blood sampling was performed and genomic DNA 
was extracted from all available relatives [Miller et al, 
1988]. Genotyping with microsatellite markers (Table 
III) involved PCR amplification of 50 ng genomic DNA 
in 15 fA IX Supertaq11 buffer 110 mM Tris-HCl, pH 9,0, 
50 mM KC1, 1.5 mM MgCla, 0.1% Triton X-100, 0.01% 
(w/v) gelatin] in the presence of ,,2P-dCTP with 0.06 U 
Supertaq11 (HT Biotechnology, Ltd, England). Amplifi­
cation was achieved by 35 cycles of 1 min at 94°C, 2 min 
at 55°C and 3 min at 72°C with the appropriate primers 
(Genome Database; Isogen Bioscience, The Nether­
lands). Subsequently, the labeled amplification prod­
ucts were separated by electrophoresis on 6.6% de­
naturing polyacrylamide gels, To visualize the allelic
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Normal
values III-3 III-6 III-7 III-9 IV-6
Somatomedin C nmol/L 12-48“ 3.5 10.3 6.7 9,7 8.21
Testosterone nmol/L 10-25 36 13 27 18.2 <2
Estradiol nmol/L 0.03-0,11 0,08 0.06 0.08 0,03 nd
Prolactin mE/L 100-700 nd 310 500 140 310
T4 nmol/L 54-154 67 91 93 72 90
Free T4 pmol/L
TSH mE/L
9-17 nd 10.3 11 nd 12,1
0.4-4,0 3,5 1.94 1.89 nd 3,8
Cortisol //mol/L morning nd nd nd 0,60 0.22
0.19-0,55
*ndf not done.
‘‘In all 5 patients ; <3rd con tile for age, 
l>Normal for his ago (prepubertal).
bands, gels were dried and exposed overnight to Kodak 
X-OMAT S film, Lod score calculations were performed 
with the Mlink option of the program LINKAGE ver­
sion 5.10 [Lathrop et al,, 1985]. Complete penetrance 
was assumed and the disease gene frequency was 
estimated at 0.00001. Allele frequencies for each of the 
markers were assumed as reported in G.DB,
RESULTS
Clinical examination demonstrated facial anomalies 
in some but not in all of the patients (Table I and Figs, 
2-5), In adult patients, gynaecomastia was seen. All 
patients were short and mentally retarded, rangingfrom 
a severe impairment necessitating admission to an in­
stitute for the mentally handicapped, to dull mentality.
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Fig. 3. Patient III-3 at the age of 50 years. Fig. 4. Pationt III-6 at the age of 45 y oars.
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Fig. 5. Patient II1-7 at the ago of 39 yearn.
On the average, untreated patients reached their final 
height, ranging from 135 to 159 cm, at the age of 24 to 
25 years (Fig. 6). In all examined patients, behaviour 
was considered infantile, and laboratory investigations 
demonstrated total IGHD (Table II). In several patients 
high resolution G- and Q-banded chromosomes were 
normal and the FRAXA CCG repeat size was normal.
Linkage analysis was performed with 2 8  highly poly­
morphic microsatellite markers distributed more or 
less evenly along the entire X chromosome. In Table III, 
the markers are listed in the Xpter~>Xqtor order based 
on the recent map of Fain et al. I’1995). Significant lod 
scores were only obtained with markers DXS294, 
DXS984 and DXS1227 indicating that the responsible 
genetic defect is located in the distal part of Xq. The 
maximum lod score was Z — 3.26 at 0 = 0.0 for marker 
DXS294. To locate the genetic defect more accurately, 
haplotypes were constructed with markers from the 
relevant region (Fig. 1). In this way, DXS425 and 
FRAXA were defined as the closest proximal and dis tal 
markers, respectively, spanning a distance of 40 cM 
and thereby excluding involvement of the FRAXE gene. 
Thus, our results demonstrate that the genetic defect 
underlying mental retardation and growth hormone 
deficiency in this family is located in Xq24-q27.3.
DISCUSSION
X-linked mental retardation with IGHD has, to our 
knowledge, not yet been described before.
Many XLMR genes have been assigned regionally 
[Neri et al., 1994]. Those assigned to Xq24-q27.3 con­
cern well-described syndromes, metabolic and neuro­
muscular disorders, which are clinically clearly differ­
ent from what is seen our patients [Neri et al., 19941. 
Of the nonspecific forms, MRX6 maps to Xq26 and 
clinically it combines mental retardation with short 
stature, “coarse" face with other fecial anomalies and 
stubby hands [Kondo et al., 1991 J. It is not stated 
whether the small body size was due to growth hor­
mone deficiency or to other causes, X-linked recessive 
panhypopituitarism is excluded in our family because 
clinical and endocrinological examinations gave no evi­
dence for general hypothalamic/hypophyseal dysfunc­
tion other than lack of growth hormone, Likewise, the 
small sella turcica as well as the size reduction of the 
pituitary gland seen in one patient on autopsy is com­
patible with an isolated deficiency of growth hormone 
producing cells, which account for most cells of the ade­
nohypophysis [Kovics and Horvath, 1986]. IGHD was 
been described previously in combination with XL A. 
XLA or Bruton type agammaglobulinemia is due to mu­
tations in the BTK gene, which is located in the Xq21.3- 
q22 interval [Duriez et al., 1994]. Our patients did not 
have an apparent increased susceptibility for infec­
tions, but, more importantly, the localization of the in­
volved genets) in this family is in a different region of 
the X chromosome, Yokoyama et al. [1992] and Ogata 
et al. [1.9921 provide evidence for the presence of genes 
involved in GH regulation to XqI3,3-q21.2 and the 
pseudoautosomal region on the distal Xp, respectively. 
Our study suggests tha t the Xq24-q27.3 interval con­
tains gene(s) involved in mental development and in 
GH regulation. The gene(s) underlying X-linked IGHD 
has (have) not been mapped yet. Therefore at least for­
mally, it is possible that in the family reported here, 
such a gene is involved, as well as a hitherto unde­
scribed gene for XLMR. For that reason wo cannot rule 
out the possibility that the combination of XLMR and 
IGHD segregating in this family as a Mendelian trait 
is a contiguous gene syndrome resulting from a mi­
crodeletion spanning two closely linked genes in the 
distal long arm of the X-chromosome, In the absence of 
independent evidence for the existence of separate 
genes for XLMR and IGHD in the relevant Xq24-q27.3 
interval, however, the alternative, i.e., that the XLMR- 
IGHD phenotype is due to pleiotropic effects of a single 
gene defect, may bo more plausible. Indeed, one form of 
XLMR with short stature has been mapped to the same 
interval [Kondo et al., 1991]. Unfortunately, the wide 
linkage interval does not yet allow reliable carrier de­
tection and prenatal diagnosis.
Only the youngest patient had GH replacement ther­
apy, with apparent success. All his untreated affected 
relatives continued to grow into their twenties, which 
can at least partly be explained by the severely re­
tarded bone age, and entered puberty without treat-
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Fig. 6, Height growth cvurvoH of patienta 11-7,1'NH, Il 1-9, und IV-6.
ment. Their final height ranged from 135 to 159 cm. A 
similar range was found by Wit et al. 11996] when pool­
ing literature and personal data on final height of un­
treated patients with severe IGHD and spontaneous 
puberty Untreated adult GH deficiency exhibits a 
whole array of metabolic effects ranging from reduced 
bone mineral content to increased cardiovascular mor­
tality. Impaired psychological well-being has been 
reported as well. GH replacement therapy can totally 
or partially alleviate these clinical consequences and 
is therefore advisable in adult GH deficient patients
[Jorgensen et al., 1994; de Boer et al., 1995]. In ade­
quately treated IGHD-patients puberty will occur at 
normal age and final height may approach target
it et al, l ï
In conclusion we report on a family in which a hith­
erto unreported combination of MR and IGHD congre­
gates in an X-linked fashion. Linkage studies suggest a 
location of the responsible gene(s) in the Xq24-q27.3 in­
terval. The regional assignment of the genetic defect in 
this family is a first step towards the elucidation of the 
underlying gene(s) and the causative mutation(s).
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Table III. Results of Two-Point Linkage Analysis*
LOD scores (0)
Marker 0 . 0 0.05 0 , 1 0 . 2 0.3 0.4
DXS1060 — oo - 3 . 2 2 - 1 . 8 8 - 0 . 7 2 - 0 . 2 1 - 0 . 0 0
GHGXg — oo - 0 . 0 8 0 . 1 1 0.19 0,15 0.08
DXS443 - 0 . 2 0 - 0 . 1 7 - 0 . 1 5 - 1 . 1 0 - 0 . 0 6 - 0 .0 3
DXS451 — OO - 0 . 5 4 - 0 . 0 7 0.25 0.29 0,19
DMD — oo - 1 . 4 8 - 0 . 9 8 - 0 . 5 5 - 0 ,3 3 - 0 .1 6
DXS538 — OO - 1 . 0 8 - 0 . 5 9 - 0 . 2 2 - 0 . 0 9 - 0 .0 3
DXS7 - 0 . 2 0 - 0 . 1 7 “ 0.15 - 0 . 1 0 - 0 . 0 6 0.03
MAO A — oo - 0 . 9 2 - 0 . 6 2 - 0 .3 1 - 0 . 1 5 —0.05
DXS1003 — oo - 0 . 2 6 0 . 2 1 0,51 0,49 0.31
ALAS2 — oo - 0 . 7 4 - 0 . 4 6 - 0 . 2 1 - 0 . 0 8 - 0 . 0 2
DXS453 — oo - 0 . 6 4 - 0 . 3 7 - 0 . 1 3 - 0 .0 3 0 , 0 0
DXS559 ™ oo - 0 . 7 4 - 0 . 4 6 - 0 . 2 1 - 0 , 0 8 - 0 , 0 2
DXS3 0 . 2 2 0 . 2 1 0.19 0.15 0 .1,1 0,06
DXS1231 — DO - 5 . 0 6 - 3 . 3 4 - 1 . 7 3 - 0 .8 7 - 0 . 3 4
DXS178 — OO - 4 . 2 0 - 2 . 5 4 - 1 . 0 6 - 0 . 3 7 - 0 ,0 6
COL4A5 “ OO - 0 . 8 8 - 0 . 5 0 - 0 . 3 7 —0.44 - 0 .3 2
DXS425 — OO 0.99 1.04 0.82 0.46 0 . 1 2
DXS424 — oo - 0 . 0 8 0 . 1 2 0 . 2 2 0.18 0 . 1 0
HPRT n,i. n.i. n.i. tITL t jl* i n.i. n.i,
DXS294 3.26 2.98 2 . 6 8 2,06 1.38 0 , 6 6
DXS984 1 . 8 8 1.74 1.60 1.27 0.90 0,47
DXS1227 2.46 2.28 2.08 1.65 1.17 0.62
DXS292 n.i. n.i. n.i. • n.i. n.i.
DXS548 n.i. n.i. n.i. n.i. n.i. n.i.
FRAXAc2 — OO - 1 . 6 8 - 0 . 6 9 0.05 0.25 0 , 2 1
DXS1113 *”“*■ oo - 1 . 4 8 - 0 . 7 1 - 0 . 1 0 0 . 1 0 0 , 1 1
G6 PD n,i. n.i. n.i. n.i. n.i. n.i.
DXS1108 n.i. n.i. n.i. n.i. n.i. n.i.
!|în.i., not informative.
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